Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Pro-Pharmaceuticals Inc. is a research leader in developing a new generation of Glyco-upgradeÔ oncologic drugs. We target sugar-specific binding sites found on cancer cells using carbohydrate technology with the goal of improving efficacy and reducing toxicity of some of the proven, commonly used anti-cancer drugs. Two platforms of technologies have been identified by Pro- Pharmaceuticals. The first is CARBOSOMEÔ with the lead product DAVANAT-1Ô, which is in Phase I human clinical trials. The second platform is UNIVERSAL CARBOHYDRATE LINKER TECHNOLOGYÔ (UCLTÔ), with the lead drug being GALACTOMYCINÔ now in pre-clinical development. ( www.pro-pharmaceuticals.com )
Pro-Pharmaceuticals , Inc.
189 Wells Avenue Suite 200
Newton, Massachusetts 02459
USA
Tel: (617) 559-0033
Fax: (617) 928-3450